Treatment of Preterm Labor with the Beta-Adrenergic Agonist Ritodrine

Publisher Website
Google Scholar
Abstract
In the Canadian study of ritodrine (July 30 issue),1 no mention is made of the power of the study to detect meaningful differences. I have calculated its statistical power for the major outcome variables and have found there to be serious problems with the conclusion reached by both the study authors and the editorialists, Leveno and Cunningham2 — i.e., that there are no significant differences between the treatment groups.